

**REMARKS**

Claims 1-18 and 21 are currently pending. Claims 1-12, 13, 16, and 21 have been amended. Claims 1 and 2 have been amended to more clearly state the inventive subject matter. Claims 3, 4, and 6 have been amended to correct clerical errors. Withdrawal and reconsideration of the rejections are respectfully requested.

**Rejections Under 35 U.S.C. §102**

Anticipation under 35 U.S.C §102 requires each and every limitation of the claim to be disclosed in a single prior art reference, either expressly or inherently. The anticipating reference must disclose the elements in the arrangement called for by the claim. If any limitation of the claim is missing, the reference does not anticipate.

Reconsideration is requested of the rejection of claims 1-2 and 18 as anticipated by Kowalski (Reference U). Claim 1 has been amended to n equals 0. Claim 2 is dependent on 1, and claims 1 and 2 as presently defined are not anticipated by Knowles. Withdrawal of the rejection is requested.

**Rejections Under 35 U.S.C. §112**

Although applicant traverses the rejection of claims 1-12, 13, 16, and 21 under 35 U.S.C. §112, the claims have been amended to eliminate the "s" at the end of "compounds", and to properly identify Y's markush group to include aryl and heteroaryl. Applicant has also amended claims 13 and 16 and 21 as requested by the Examiner. There is no basis in the action to support the notion that one of ordinary skill in the art would not have understood the scope of the claims as is necessary to support the 35 U.S.C. §112 rejections. While the choice of language may not have been consistent, the inconsistency was not such that one of ordinary skill in the art would not have understood the scope of the claim. The amendment corrects the objectionable form. Should the examiner disagree with this distinction and remain of the opinion that the appropriate way to deal with claims 1-12, 13, 16, and 21 were by section 112 rejection and not by objection, it is requested that applicant be so advised. Otherwise, applicant will assume that the examiner agrees with applicant's position.

The application is considered to be in condition for allowance and such action is solicited.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'Mark E. Baron', is written over a horizontal line.

Mark E. Baron  
Attorney for Applicants  
Reg. No. 46,150

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(617) 871-3216  
Date: July 2, 2007